英文药名：Teribone(Teriparatide Acetate Inj)

中文药名：醋酸特立帕肽注射剂

生产厂家：旭化成制药
药品介绍
产品名称：Teribone™56.5微克皮下注射
通用名：醋酸特立帕肽
适应症：骨质疏松症与骨折的高风险
剂量和给药：对于成年人，每周一次通常以单一56.5微克注射长达72周。
制造：旭化成制药公司

注：使用以原处方为准：http://www.info.pmda.go.jp/go/pack/2439401D2024_1_04/
Launch of Teribone™ osteoporosis drug in Japan
Asahi Kasei Pharma has launched the sale of a 56.5 µg subcutaneous injection formulation of Teribone™ (generic name: teriparatide acetate) for the indication of osteoporosis with high risk of fracture, upon listing in the NHI Drug Price Standard today.
Teribone™ is a human parathyroid hormone preparation that facilitates bone formation. A Phase III clinical trial in Japan demonstrated that, with weekly subcutaneous injections for 72 weeks, Teribone™ decreased the risk of developing new vertebral fracture1 by 78.6% compared to placebo treatment. The efficacy in preventing fracture is obtained by increasing bone strength with both improved bone quality and increased bone mass. Asahi Kasei Pharma obtained approval for the manufacture and sale of Teribone™ in Japan on September 26, 2011, having filed an application for approval on October 20, 2010.
In Japan, it is estimated that more than 11 million people suffer from osteoporosis, including those not receiving treatment,2 and the number is increasing as the population ages. Since osteoporosis carries an increased risk of vertebral and femoral fracture, with a high probability of resulting in confinement to bed, the implementation of effective measures against osteoporosis is an important social issue.
Asahi Kasei Pharma believes that, with its efficacy in preventing fracture, Teribone™ will make a significant contribution to the treatment of osteoporosis.
-----------------------------------------------
产地国家: 日本
原产地英文商品名:
Teribone Injection(テリボン皮下注用) 56.5ug
原产地英文药品名:
Teriparatide Acetate
中文参考商品译名:
Teribone注射剂(テリボン皮下注用) 56.5微克/支
中文参考药品译名:
特立帕肽
生产厂家中文参考译名:
旭化成制药
生产厂家英文名:
Asahi Kasei Pharma Co., Ltd.